Phaseline

Companies › ABL Bio

ABL Bio: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ABL103
Toll-like receptor 7/8 agonist
–Phase 1Advanced Solid Tumor; Solid TumorsNov 2027
ABL503–Phase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04762641ABL503Phase 1Advanced Solid TumorOncologyNov 2025
NCT06126666ABL103Phase 1Advanced Solid TumorOncologyNov 2027
NCT07158918ABL103Phase 1Solid TumorsOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.